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Abstract
Chronic sympathetic nervous system activation results in increased angiogenesis and tumor growth in orthotopic
mouse models of ovarian carcinoma. However, the mechanistic effects of such activation on the tumor vascula-
ture are not well understood. Dopamine (DA), an inhibitory catecholamine, regulates the functions of normal and
abnormal blood vessels. Here, we examined whether DA, an inhibitory catecholamine, could block the effects of
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chronic stress on tumor vasculature and tumor growth. Exogenous administration of DA not only decreased tumor
microvessel density but also increased pericyte coverage of tumor vessels following daily restraint stress in mice.
Daily restraint stress resulted in significantly increased tumor growth in the SKOV3ip1 and HeyA8 ovarian cancermod-
els. DA treatment blocked stress-mediated increases in tumor growth and increased pericyte coverage of tumor en-
dothelial cells. Whereas the antiangiogenic effect of DA is mediated by dopamine receptor 2 (DR2), our data indicate
that DA, through DR1, stimulates vessel stabilization by increasing pericyte recruitment to tumor endothelial cells. DA
significantly stimulated migration of mouse 10T1/2 pericyte-like cells in vitro and increased cyclic adenosine mono-
phosphate (cAMP) levels in these cells. Moreover, DA or the DR1 agonist SKF 82958 increased platinum concentra-
tion in SKOV3ip1 tumor xenografts following cisplatin administration. In conclusion, DA stabilizes tumor blood vessels
through activation of pericyte cAMP–protein kinase A signaling pathway by DR1. These findings could have implica-
tions for blocking the stimulatory effects of chronic stress on tumor growth.
Neoplasia (2013) 15, 502–510
Introduction
There is growing recognition of the stimulatory effects of chronic
stress on tumor growth. The sympathetic nervous system is activated
in response to chronic stress, with resultant increases in stress hormones
such as norepinephrine (NE) and epinephrine (E) [1,2]. We have
recently demonstrated that both of these catecholamines are ele-
vated in a sustained fashion in ovarian and other peritoneal tissues
in preclinical models of chronic stress [3]. These hormonal increases
were associated with greater tumor burden, which was mediated by
increased tumor angiogenesis. The β-adrenergic cyclic adenosine
monophosphate (cAMP) signaling pathway was identified as the
underlying signaling pathway responsible for angiogenesis in these
malignant ovarian tumors [3]. Recent evidence suggests that the
third catecholamine, dopamine (DA), has an effect opposite to that
of NE and E with regard to tumor angiogenesis, growth, and the
development of ascites [4,5]. In vivo and in vitro studies have shown
that DA, through its specific dopamine receptor 2 (DR2), inhibits
tumor growth by suppressing the actions of vascular permeability
factor/vascular endothelial growth factor A on both tumor endo-
thelial cells and bone marrow–derived endothelial progenitor cells
[6]. DA can also inhibit the mobilization of endothelial progenitor
cells from the bone marrow [7]. We have previously described that
DA levels are decreased in ovarian carcinomas from stressed mice
and that DA replacement counteracts the stimulatory effects of NE
and E on tumor growth by inhibiting tumor angiogenesis [8]. We
have also demonstrated that DA replacement can block the stimula-
tory effects of sympathetic mediators on ovarian cancer growth [8].
However, the mechanisms by which DA affects tumor vasculature are
not fully understood.
Our previous studies have shown that pericyte coverage was de-
creased in tumor vessels from stressed animals. Therefore, we wondered
whether DA could block such stress-mediated effects. Pericytes are
attached to endothelial cells and are critical for the development of a
functional vascular network [9]. The exact molecular mechanisms
mediating pericyte coverage are not fully understood and its biologic
relevance in tumors is currently being investigated. Here, we examined
whether DA could also block the adverse effects of chronic stress on
tumor vasculature by stimulating pericyte recruitment and promoting
tumor vessel maturation.
Materials and Methods
Reagents
DA, bromocriptine (DR2 agonist), eticlopride (DR2 antagonist),
SKF 3839 (DR1 agonist), butaclamol (DR1 antagonist), KT 5720
[protein kinase A (PKA) inhibitor], H89 (PKA inhibitor), dibutyryl
cAMP (dbcAMP; PKA activator), and NE were obtained from
Sigma-Aldrich (Detroit, MI); recombinant human vascular endothelial
growth factor was obtained from R&D Systems (Minneapolis, MN).
Annexin V and TUNEL staining kits were purchased from Pharma BD
(Franklin Lakes, NJ) and Promega (Madison, WI), respectively.
Cell Lines and Culture Conditions
The ovarian cancer cells (SKOV3ip1 and HeyA8) were main-
tained in RPMI 1640 supplemented with 15% FBS and 0.1% genta-
micin sulfate (Gemini Bioproducts, Calabasas, CA) [10,11]. Murine
pericyte-like cell line 10T1/2 (embryonic fibroblasts) was obtained
from American Type Culture Collection (ATCC, Manassas, VA;
CCL-226). Endothelial cells isolated from the ovary of the immorto-
mouse (MOEC) [12] were maintained in Dulbecco’s modified Eagle’s
medium with 10% FBS.Mouse pericyte-like cells (10T1/2) were main-
tained in Dulbecco’s modified Eagle’s medium with 10% FBS and glu-
tamine. All in vitro experiments were conducted when cells were at
60% to 80% confluence, unless otherwise specified. For in vivo injec-
tions, cancer cells were trypsinized and centrifuged at 1000 rpm for
7 minutes at 4°C, washed twice, and reconstituted in Hank’s balanced
salt solution (Gibco, Carlsbad, CA).
Reverse Transcription–Polymerase Chain Reaction
Analysis of DRs
Total RNA was isolated by using a Qiagen RNeasy Kit (Valencia,
CA). cDNA was synthesized by using the SuperScript First-Strand
Kit (Invitrogen, Eugene, OR) as per the manufacturer’s instruc-
tions. cDNA was subjected to polymerase chain reaction (PCR) analy-
sis using specific primer sequences for murine DRs (DR1–DR5).
These primer sequences were designed on the basis of the reported
National Center of Biotechnology Information nucleotide sequences
using OligoPerfect software (Invitrogen). β-Actin was used as a
housekeeping gene.
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Chronic Stress Model and Treatment Schema
Female athymic nude mice (10 to 12 weeks old) were obtained from
the US National Cancer Institute. All experiments were approved by
the Institutional Animal Care and Use Committee of The University
of Texas MD Anderson Cancer Center. The mice were experimen-
tally stressed by being restrained for 2 hours everyday using a well-
characterized restraint system in which periodic immobilization induces
high levels of hypothalamic-pituitary-adrenal and sympathetic nervous
system activities, characteristic of chronic stress [3]. Ovarian cancer cells
were injected intraperitoneally (i.p.) into the mice 7 days after starting
daily stress. Then, the mice were further divided into treatment groups
(10 animals/group) as follows: 1) phosphate-buffered saline (PBS;
control), 2) DA (75 mg/kg daily i.p.), 3) DA plus butaclamol (DR1
antagonist; 1.5 mg/kg daily i.p.), and 4) DA plus eticlopride (DR2
antagonist; 10mg/kg daily i.p.). Following 3 weeks (SKOV3ip1model)
and 2 weeks (HeyA8 model) of treatment, the mice were killed and
their tumors were excised. Tumor weight and number of tumor nodules
were recorded, and tumor and relevant tissue samples were collected.
Concentration of Platinum in Tumors Following
Cisplatin Administration
Female nude mice bearing SKOV3ip1 tumors (∼3 weeks after
cell implantation) were injected (i.p.) daily for 6 days with PBS,
DA (75 mg/kg), or the DR1 agonist SKF 82958 (1 mg/kg), and
30 minutes after the final injection, mice also received 7 mg/kg
cisplatin (i.p.). Animals were sacrificed 6 hours later and samples
(20–120 mg) from tumor (from three different peritoneal sites), left
kidney cortex, and liver were excised, rinsed in ice-cold PBS, gently
blotted dry, weighed, and processed for platinum (Pt) determination
by flameless atomic absorption spectrophotometry, as previously de-
scribed [13,14]. Briefly, samples were solubilized overnight in two
volumes of benzethonium hydroxide at 55°C, acidified with 0.3 N
HCl to give a final tissue concentration of 12.5 mg/ml, and analyzed
for Pt levels against standard curves prepared with control tissue and a
certified Pt standard (Sigma). The averaged Pt level in tumor samples
are presented as tumor/kidney and tumor/liver ratios to normalize for
any variation in cisplatin absorption and distribution affected by
tumor mass.
Analysis of Angiopoietin 1 mRNA Expression
A quantitative reverse transcription (RT)–PCR assay was used
to measure angiopoietin 1 (Ang1) mRNA in RNA extracted from
SKOV3ip1 tumor tissues using primers designed for Ang1 isoform 1:
sense, 5′-CACAACTATGATGATTCG-3′; antisense, 5′-TTCACATA-
ACTACCACTTA-3′, and for Ang1 isoform 2: sense, 5′CACAACTAT-
GATGATTCG-3′; antisense, 5′TTCACATAACTACCACTTA-3′.
Total RNA was isolated using a Qiagen RNeasy Kit. RT of 1 μg of
total RNA was performed using the Verso cDNA (Thermo Scientific,
Albany, NY). 18S was using as a housekeeping gene to normalize
Ang1 mRNA levels. Relative quantification values were normalized
to a housekeeping gene (18S ) according to the 2−ΔΔCt comparative
threshold cycle (Ct) method [15].
cAMP Determination
The effect of DA on cAMP accumulation was examined by exposing
cells to 0, 10, and 50 μM DA for 30 minutes at 37°C. cAMP levels
were measured in total cell lysates using an enzyme immunoassay kit
(Biomol, Plymouth, PA).
Cell Migration Assay
Migration into a gelatin-coated membrane matrix was assessed using
the Membrane Invasion Culture System, as previously described [16].
A total of 1.5 × 105 SKOV3ip1 cells were loaded into the upper cham-
ber in media only or in media containing the stimulant of interest. The
following reagents were used in these experiments: DA (10 μM); NE
(10 μM); PDGF-BB (10 ng/ml); SKF38393, butaclamol, and eticlo-
pride (50 μM); and KT 5720, H89, and dbcAMP (10 μM). Cells were
allowed to invade in a humidified incubator for 5 hours. Cells that had
invaded through the basement membrane were collected, stained, and
counted by light microscopy in five random fields (original magnifica-
tion, ×200) per sample.
Western Blot and Immunoprecipitation Analyses
Western blot analysis was performed as previously described [17].
Briefly, lysates from cultured cells were prepared using modified RIPA
buffer, and the protein concentrations were determined using a BCA
Protein Assay Reagent Kit (Pierce Biotechnology, Rockford, IL). Protein
lysates were subjected to 10% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis separation and transferred to a nitrocellulose
membrane. Blots were probed with primary antibodies specific for
DR1 and DR2 (Santa Cruz Biotechnology, Delaware, CA) and HRP-
conjugated secondary antibody (Amersham, Piscataway, NJ) and sub-
sequently developed with an enhanced chemiluminescence detection
kit (ECL; Pierce Biotechnology). To confirm equal protein loading,
membranes were stripped and reprobed with an anti–β-actin antibody
(Sigma-Aldrich). To examine the association between Gαs protein and
mDR1, pericyte cells were exposed to 10 μMDA for 0, 10, and 20min-
utes at 37°C. Cell lysates were then prepared and immunoprecip-
itated with DR1 antibody (Santa Cruz Biotechnology) at 4°C for
14 hours. Immunocomplexes were captured with 2% protein A agarose
beads (Upstate, Lake Placid, NY). Protein was eluted in reducing
sample Laemmli buffer, subjected to 10% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis separation and transferred to a nitro-
cellulose membrane. Anti-Gαs (Abcam, Cambridge, MA) was used as
primary antibody. Immunodetection of Gαs protein was performed as
described above.
Immunohistochemical Analysis
Analysis of microvessel density (MVD) and assessment of tumor
and endothelial cell apoptosis were performed as previously described
[12,17–19]. Dual immunofluorescence staining for CD31 (red) and
desmin (green) was performed as previously described [20]. Briefly,
frozen tumor sections were fixed in cold acetone for 30 minutes and
blocked with a protein blocker (4% fish gel). These sections were then
probed with CD31 antibody (1:500; BD Pharmingen, San Diego, CA)
at 4°C overnight. After washing with PBS, the sections were incubated
with Alexa 594–conjugated anti-rat antibody (1:1000; Invitrogen)
for 1 hour at room temperature. After extensive washing with PBS,
the samples were then probed with anti-desmin antibody (1:400;
DakoCytomation, Copenhagen, Denmark) for 2 hours, followed by
washing with PBS and incubation with Alexa 488–conjugated anti-
rabbit antibody (1:1000; Invitrogen) for 1 hour at room temperature.
The samples were counterstained with Hoechst. Vessels with at least
50% coverage of associated desmin-positive cells were considered pos-
itive for pericyte coverage. Double immunofluorescence for DR1/G
protein signaling 5 (RGS5) and for DR1/desmin was performed in
frozen tissue sections as follows: After acetone fixation and blocking
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with gelatin (4%), tissues were incubated with rabbit DR1 antibody
(Santa Cruz Biotechnology; 1:100) at 4°C overnight. Samples were
washed in PBS and incubated with blocking solution for 10 minutes
and then with a goat anti-rabbit Alexa 488 antibody (1:1000)
for 1 hour. Afterward, tissues were processed for the detection of
RGS5 and desmin, as previously described [18,20]. Dual immuno-
fluorescence staining for Ang1/RGS5 in frozen tumor tissues was
performed following the procedure described above and using
primary antibodies: rabbit anti-Ang1 antibody and goat anti-RGS5
(Santa Cruz Biotechnology).
Immunofluorescence and Confocal Microscopy
Immunofluorescence microscopy was performed using a Zeiss
Axioplan fluorescence microscope (Carl Zeiss, Inc, Thornwood, NY)
equipped with a 100-W Hg lamp and narrow band-pass excitation
filters. Representative images were obtained using a cooled charge-
coupled device Hamamatsu C5810 camera (Hamamatsu Photonics,
Bridgewater, NJ) and Optimas software (Media Cybernetics, Silver
Spring, MD). Confocal fluorescence images were collected using 20×
objectives on a Zeiss LSM 510 laser scanning microscopy system (Carl
Zeiss Inc) equipped with a motorized Axioplan microscope, argon laser
(458/477/488/514 nm, 30 mW), HeNe laser (413 nm, 1 mW and
633 nm, 5 mW), LSM 510 control and image acquisition software,
and appropriate filters (ChromaTechnology Corp, Brattleboro, VT).
Composite images were constructed with Photoshop software (Adobe
Systems, Inc, Mountain View, CA).
Statistical Analysis
Continuous variables were compared using Student’s t test (between
two groups) or analysis of variance (for all groups) if the variables
were normally distributed and the Mann-Whitney rank sum test if
the distributions were nonparametric. For the in vivo therapy
experiments, 10 mice were used in each group, and a P < .05 on
two-tailed testing was considered significant. To control for the effects
of multiple comparisons, a Bonferroni adjustment was made; for that
analysis, a P value ≤ .017 was considered statistically significant.
Results
Expression of DA and β-Adrenergic Receptors in
Murine Pericyte-Like Cells and in MOEC
Because DA can signal through multiple receptors, we first exam-
ined the RNA expression of DRs (mDR1–mDR5) in mouse 10T1/2
pericyte-like cells and in MOEC (Figure W1A). All five DRs were
detected in both murine cell lines. DR1 and DR2 are the prototypes
of the DR1 and DR2 subfamily of DRs, which mediate stimulatory
and inhibitory effects in cells, respectively. Protein expression of
mDR1 and mDR2 was confirmed byWestern blot analysis in MOEC
and 10T1/2 cells (Figure W1B). RNA expression of the β-adrenergic
receptors ADRB1 and ADRB2 was also detected in both cell lines
(Figure W1C ).
DA Inhibits Stress-Mediated Tumor Growth and Stimulates
Pericyte Coverage of Tumor Vasculature
On the basis of the known antiangiogenic effects of DA, we assessed
the biologic consequences of DA in the context of chronic stress using
a well-characterized daily restraint stress model. SKOV3ip1 tumor–
bearing nude mice (n = 10 mice per group) were treated according
to the following groups: 1) control PBS, 2) DA, 3) DA + butaclamol
(DR1 antagonist), or 4) DA + eticlopride (DR2 antagonist), under
both no stress and stress conditions. Consistent with prior results, daily
restraint increased tumor growth by 2.2-fold (P < .001; Figure 1A).
While DA had no significant effect on tumor growth in the absence
of stress, in mice exposed to daily restraint stress, DA treatment resulted
in a 78% reduction in tumor growth compared to control (P < .01). A
44% reduction in the number of tumor nodules (P < .05) was also
observed with DA treatment (Figure 1A). The inhibitory effect of
DA on tumor growth was abrogated by the addition of the DR2 antag-
onist eticlopride but not the DR1 antagonist butaclamol. Given the
known effects of catecholamines on angiogenesis, we examined
MVD in the SKOV3ip1 tumors harvested from the treatment groups.
In stressed mice, DA treatment resulted in a significant decrease of
MVD compared to controls (P < .05; Figure 1A). This effect was also
abrogated by DA plus eticlopride (DR2 antagonist) treatment but not
by DA plus butaclamol (DR1 antagonist). This finding confirmed that
the inhibitory effect of DA on angiogenesis is mediated by DR2.
Tumor vessels with at least 50% coverage of associated desmin-positive
cells were considered positive for pericyte coverage. In stressed mice,
daily DA treatment resulted in a significant increase in pericyte coverage
compared to the control group (two-fold; P < .001). This effect was
abrogated by the addition of butaclamol to DA treatment (44%; P <
.01) but not by DA plus eticlopride treatment (Figure 1A). This finding
suggests that DA stimulates pericyte coverage through DR1. To deter-
mine the consistency of the observed effects, we used the HeyA8
ovarian cancer model. The effects of DA on tumor growth and
MVD were similar to those described above for the SKOV3ip1 model
(Figure 1B). In the HeyA8 model, DA increased pericyte coverage by
3.8-fold (P < .001), which was abrogated by addition of butaclamol
(Figure 1B). Representative images of CD31/desmin staining of tissues
from the different treatment groups (nonstressed and stressed mice) are
shown in Figure 1C . Collectively, these data suggest that DA acts
through DR1 to stimulate pericyte recruitment to tumor endothelial
cells. To further examine the signaling pathway by which DA stim-
ulates tumor vessel maturation, we evaluated pericyte coverage of
SKOV3ip1 tumor tissues from mice treated with DA, DR1 agonist
SKF 82958, and DR2 agonist parlodel. Tumor tissues from mice
treated with DA and SKF 82958 revealed a significantly increased
extent of pericyte coverage compared to the control group. Tissues from
the parlodel group showed an increase in pericyte coverage; however,
this increase was not statistically significant compared to controls
(Figure W2).
Next, we examined the impact of DA on tumor hypoxia. For this
purpose, frozen sections of SKOV3ip1 tumors from stressed mice
were immunostained for carbonic anhydrase 9 (CA9). Figure W3
shows representative images (100×) from SKOV3ip1 tumor tissues
stained for CA9. Tumor tissues from mice treated with DA revealed
reduced areas of hypoxia in comparison with tumor tissues from
nontreated (NT) stressed mice.
DA or SKF 82958 Increases Tumor Cisplatin Concentration
and Enhances the Efficacy of Cisplatin Therapy
Pt concentration was determined in SKOV3ip1 tumor tissues
6 hours after cisplatin administration when tissue distribution of this
Pt drug has stabilized [21]. The present study indicates that tumor
levels of Pt are generally lower than in the liver or kidney, and this is
apparent from the tumor/liver (Figure 2A) and tumor/kidney ratios
Neoplasia Vol. 15, No. 5, 2013 Effects of Dopamine on Ovarian Cancer Vasculature Moreno-Smith et al. 505
(Figure 2B) of <0.2. However, both DA and the DR1 receptor
agonist SKF 82958 increased the ratio two-fold or more (P < .05
and P < .001), and this indicates that these vascular stabilizing agents
selectively increase Pt levels in the tumor. To determine whether DA
or SKF 82958 increase the efficacy of cisplatin in inhibiting tumor
growth, SKOV3ip1 tumor–bearing stressed mice (n = 5 mice per
group) were treated according to the following groups: 1) control
PBS, 2) cisplatin, 3) cisplatin + DA, or 4) cisplatin + SKF 82958
and SKF 82958 alone. Compared to the control group, all treatment
groups significantly inhibited tumor growth. The combined therapy of
Figure 1. DA decreases stress-stimulated angiogenesis through DR2 and increases pericyte coverage through DR1. (A and B) Tumor
weight and tumor nodules in nonstressed and stressed mice bearing SKOV3ip1 and HeyA8 tumors treated with PBS (control), DA, DA +
butaclamol, or DA + eticlopride. DA significantly blocked tumor growth and reduced the number of tumor nodules in stressed mice
from both ovarian cancer models. This effect was abrogated by the combined treatment of DA + eticlopride. Data are the means ± SE;
n = 10 mice/group. *P < .05 compared with stress controls, †P < .05 compared to DA-treated mice. MVD was significantly decreased
by DA treatment in SKOV3ip1 and HeyA8 tumor tissues of stressed mice (*P < .05 compared with stress controls). DA + eticlopride
treatment significantly reversed DA inhibitory effect on MVD compared with DA-treated mice (†P < .05), which was evaluated by
immunohistochemical analysis of CD31 (3,3′-diaminobenzidine) staining. Microvessels were counted in five fields (200×) of each tissue
sample (n= 5). Values are means ± SE. Compared with nonstressed mice, pericyte coverage of tumor endothelial cells was significantly
increased by DA treatment in tumor tissues (SKOV3ip1 and HeyA8) of stressed mice (*P < .001). The combined treatment of DA +
butaclamol significantly reversed the stimulatory effect of DA on pericyte coverage (†P < .01). (C) Representative images (200×) from
tumor tissues of the different mouse groups stained for CD31 (vessels—red fluorescence) and desmin (pericytes—green fluorescence).
Vessels with at least 50%coverage of associated desmin-positive cells were considered positive for pericyte coverage. Percentage of tumor
vessels with pericyte coverage was evaluated in five fields (200×) of each tissue sample (n = 5). Values are means ± SE.
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cisplatin + DA and cisplatin + SKF 82958 significantly increased the
cisplatin efficacy by six-fold and five-fold, respectively (Figure 2C ).
DA Treatment Does Not Affect Ang1 Expression in
Ovarian Cancer Tumors
Given the importance of Ang1 as a signal for blood vessel stabili-
zation [22–24], we also examined Ang1 expression in SKOV3ip1
tumor tissues from stressed mice treated with DA or DR1 and
DR2 agonists. The results from these studies showed no significant
changes in the mRNA and protein expression of Ang1 in tumor tis-
sues from all treatment groups compared to the control group
(Figure W4). This finding suggests that in ovarian carcinomas,
Ang1 expression is not involved in the DA-stimulated effect on peri-
cyte coverage and tumor vessel stabilization.
Catecholamines Affect Migration of Pericytes
Considering the in vivo effects of DA, that is, the promotion of
pericyte coverage of tumor vasculature in stressed mice, we next
analyzed the in vitro effects of DA, NE, DA plus NE, DA plus
DR1 and DR2 antagonists, and the DR1 agonist SKF38393 in
10T1/2 cells. PDGF-BB was used as a positive control for stimulation
of pericyte migration. Compared to NT cells, 10 μMDA significantly
increased (1.5-fold; P < .001) the number of migrating pericytes (Fig-
ure 3). In contrast, 10 μM NE showed the opposite effect, signifi-
cantly decreasing pericyte migration (30%; P < .01). In the
presence of both DA and NE, pericyte migration was significantly
greater, not only compared to NT cells (73%; P < .001) but also com-
pared to DA treatment alone (20%; P < .01). The combined treat-
ment of DA plus butaclamol (50 μM; DR1 antagonist) significantly
abrogated the stimulatory effect of DA on pericyte migration (35%;
P < .001). However, DA plus eticlopride (50 μM), a DR2 antagonist,
did not reverse the DA effect. The DR1 agonist SKF38393 and
PDGF-BB both stimulated migration (by 1.6-fold and 1.9-fold, re-
spectively) compared with NT cells (Figure 3). These data further
suggest that stimulation of pericyte migration by DA is mediated spe-
cifically through DR1. Migration of MOEC was also examined under
the experimental conditions described above. In the presence of DA,
migration of MOEC decreased, but treatment with NE and DA plus
NE did not induce significant changes in MOEC migration com-
pared to NT cells (Figure W5).
DA and NE Regulate cAMP Levels in 10T1/2 Cells
DA, acting through G protein–coupled receptors, exerts stimula-
tory (through DR1 and DR5) or inhibitory (through DR2, DR3,
and DR4) effects on adenylate cyclase, leading to increased or de-
creased cAMP levels, respectively. However, NE induces changes
in cAMP production through α- or β-adrenergic receptors. Thus,
cAMP levels in cells are regulated by activation of both dopaminergic
and adrenergic receptors. We examined the effects of DA and NE on
cAMP production in 10T1/2 cells at different time points (10, 20,
Figure 2. DA or SKF 82958 increases tumor cisplatin concentration and enhance the efficacy of cisplatin therapy. Nude stressed mice
bearing SKOV3ip1 tumors treated with DA or DR1 agonist SKF 82958 for 6 days show significantly increased concentration of intra-
tumoral cisplatin 6 hours after cisplatin injection. The averaged Pt level in tumor samples are presented as (A) tumor/liver and (B) tumor/
kidney ratios to normalize for any variation in cisplatin absorption and distribution affected by tumor mass (n = 5; values are means ±
SE; *P< .05; **P < .001). (C) Compared to the control group, all treatment groups significantly inhibited tumor growth, *P< .01; **P <
.001; †P < .0001; the combined therapy of cisplatin + DA and cisplatin + SKF 82958 significantly increased the cisplatin efficacy by six-
fold and five-fold, respectively (n = 5; values are means ± SE).
Figure 3. Effect of DA and various DA agonists and antagonists on
10T1/2 pericyte cells. DA and the DR1 agonist SKF38393 signifi-
cantly stimulated 10T1/2 cell migration (*P < .05 compared with
NT cells); butaclamol, a DR1-specific antagonist, abrogated the
DA stimulatory effect on pericyte migration (†P < .05 compared
with DA-treated cells), whereas eticlopride, a DR2-specific antag-
onist, did not affect cell migration. Representative images (200×)
from pericyte cells were treated with the different compounds.
Values are means ± SE of three independent experiments.
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and 40 minutes) after DA exposure. DA (10 μM) resulted in a 1.8-fold
(P < .05) increase in intracellular cAMP levels after 10 minutes of
incubation (Figure 4A). This stimulatory effect was abrogated by the
DR1 antagonist butaclamol (Figure 4A). Exposure of 10T1/2 cells to
DA plus the DR2 antagonist eticlopride resulted in a 3.5-fold increase
in cAMP levels after 10 minutes of exposure. cAMP levels then de-
creased at 20 and 40 minutes after treatment. The effects of NE and
NE plus DA were also examined in 10T1/2 pericyte-like cells
(Figure 4B). At 10 and 40 minutes after NE (10 μM) exposure, cAMP
levels were 2.5-fold and 1.6-fold higher, respectively, than in NT cells.
Increases in cAMP levels of 1.2-fold, 1.6-fold, and 1.6-fold were iden-
tified in the presence of NE plus DA at 10, 20, and 40 minutes, respec-
tively. These results indicate that DA increases intracellular cAMP
levels in 10T1/2 cells throughDR1. This suggests that DA acts through
the DR1-cAMP signaling pathway to exert its in vivo stimulatory effects
on pericyte recruitment to tumor endothelial cells. In the presence of
NE plus DA, cAMP levels remained higher at all exposure times com-
pared to those in NT cells (Figure 4B). These data further suggest that
in stressed mice treated with DA, the stimulatory effects of NE and DA
on cAMP production lead to consistently elevated cAMP levels that
promote pericyte coverage and maturation of tumor vessels.
DA Stimulates Pericyte Recruitment through a
DR1-cAMP-PKA Signaling Pathway
Our data described above indicated the potential role of DR1 in
the DA-mediated stimulation of pericyte migration. To further ad-
dress this question, we examined the association between DR1 and
Gαs in the absence or presence of DA. The binding of DR1 to Gαs
protein was 1.5-fold greater in cells treated with DA for 10 minutes
than in NT cells. Figure 5A shows a representative image from three
independent immunoprecipitation experiments. This finding further
points to the DR1-Gαs-cAMP signaling pathway for the impact of
DA on pericyte function. DR1 and Gαs protein were detected in
10T1/2 cells by immunofluorescence staining in the absence and
presence of DA (Figure 5B). Pericytes exposed to DA for 10 minutes
showed an elongated, fibroblastic morphology compared to untreated
cells. This change of cell morphology suggests that DA stimulates
rearrangement of the cytoskeleton before pericyte migration. The lo-
calization of DR1 in pericytes was confirmed in 10T1/2 cells by dou-
ble immunofluorescence staining for detection of RGS5 (pericyte
marker) and DR1 (Figure 5C ). In addition, colocalization of DR1
with desmin was detected in SKOV3ip1 tumors immunostained for
desmin and DR1 (Figure 5C ).
To determine whether activation of PKA is essential for stimulat-
ing pericyte migration after the activation of the DR1-cAMP signal-
ing pathway by DA, we analyzed the effect of PKA inhibitors such as
H89 and KT5720 on 10T1/2 cell migration. In combination with
DA, each PKA inhibitor (10 μM) significantly abrogated the stimu-
latory effect of DA on pericyte migration (25–30%; P < .05).
dbcAMP, a PKA activator, was used as a positive control for pericyte
migration (Figure 5D).
Discussion
The key finding from this work is that DA, an antiangiogenic neuro-
transmitter, promotes maturation of ovarian cancer vasculature by
enhancing pericyte recruitment to tumor endothelial cells during
chronic stress. Tumors from mice exposed to chronic stress show nu-
merous and tortuous immature blood vessels. In a previous study [8],
we reported that DA, acting through DR2, blocked the stimulatory
effects of chronic stress on ovarian cancer growth by inhibiting tumor
angiogenesis and stimulating tumor cell apoptosis. These effects were
mediated by inhibition of Src activation. Here, we show that DA
replacement also promotes the normalization of tumor vasculature
in ovarian cancer stress models and allows greater uptake of cisplatin.
Our studies indicate that DA treatment counterbalances the negative
effects of stress hormones and remodels the tumor vasculature. It is
likely that that under stress conditions, tumor cells might be more
responsive to DA replacement due to depletion of endogenous DA
under such conditions.
The physiological actions of DA are mediated by at least five dis-
tinct G protein–coupled receptor subtypes. Two DR1-like receptor
subtypes (DR1 and DR5) couple to the Gαs, activate adenylate cy-
clase, and increase cAMP levels. The other receptor subtypes belong
to the DR2-like subfamily (DR2, DR3, and DR4) and are prototypic
of G protein–coupled receptors that inhibit adenylate cyclase and de-
crease cAMP production. The MOEC and 10T1/2 cells tested in
this work showed expression of DR1- and DR2-like DRs, indicating
that DA might regulate stimulatory and/or inhibitory processes in
these cells. Previous studies suggest that some antiangiogenic agents
can also transiently “normalize” the abnormal structure and function
of tumor vasculature to make it more functional for oxygen and drug
delivery [25–27]. The transient normalization of tumor vessels pro-
duces a temporary increase in oxygen and nutrient delivery for cancer
cells that surround these “normalized” vessels. Theoretically, such
changes might be expected to enhance the proliferation of these cells
and, hence, to accelerate tumor growth, but this notion is not sup-
ported by published data [25]. Drugs that induce vascular normaliza-
tion can alleviate hypoxia andmay increase the efficacy of conventional
cancer therapies. Therefore, a better understanding of the molecular
and cellular mechanisms of vascular normalization could lead to more
Figure 4. cAMP levels in 10T1/2 cells are regulated by DA and NE
through DRs and adrenergic receptors. (A) DA exposure for 10 min-
utes resulted in a 1.8-fold (*P < .05) increase in cAMP levels com-
pared with NT cells. This DA stimulatory effect was reversed by
DA+ butaclamol treatment (†P< .05). In contrast, DA+ eticlopride
induced a greater accumulation of cAMP by inhibiting the DR2-
mediated suppressive effect on cAMP production. After long expo-
sure (40 minutes), there was no longer an effect of DA, and cAMP
levels were similar to those in NT cells. (B) After 10 minutes of
exposure, NE and DA alone increased cAMP levels by 2.5-fold
and 1.8-fold (*P < .05), respectively. NE + DA treatment showed
a 1.2-fold increase of cAMP levels. After 20 to 40 minutes of expo-
sure, cAMP levels decreased in all three cell treatments. At 40 min-
utes of exposure, cAMP accumulation in DA-treated cells was
similar to that in NT cells. In contrast, cAMP levels remained
increased (1.6-fold) in both NE− and NE + DA–treated cells com-
pared to NT cells (*P < .01).
508 Effects of Dopamine on Ovarian Cancer Vasculature Moreno-Smith et al. Neoplasia Vol. 15, No. 5, 2013
effective therapies for not only cancer but also other diseases with
abnormal vasculature.
The second messenger cAMP and its effector, PKA, mediate the
regulation of many processes, including glycogenolysis, ion transport,
gene transcription, and cell proliferation and differentiation [28–30].
Increased levels of intracellular cAMP also cause reorganization of the
actin cytoskeleton in REF52 fibroblasts [31] and a marked alteration
of epithelial cells [32]. Our study demonstrates that DA, through
DR1, promotes pericyte migration in vitro and pericyte recruitment
to tumor endothelial cells in vivo. Butaclamol, a DR1-specific antag-
onist, abrogated the DA-stimulated effect on pericytes under both
experimental conditions. This DR1-mediated normalization of vas-
culature by DA is important for antitumor drug distribution to the
tumor, and this was clearly seen with cisplatin, which is likely to en-
hance antitumor effects. More importantly, the increase in tumor
Pt levels was selective, and not observed in liver and kidney, which
is likely to increase the therapeutic index. Similar effects of DA on
increased uptake of 5-fluorouracil have also been reported [24]. Mech-
anistic studies in the present manuscript indicated that the cAMP-
PKA signaling pathway is involved in the DA-mediated effect on
pericytes. 10T1/2 pericyte-like cells treated with DA showed increased
levels of cAMP and greater pericyte migration. In addition, cAMP
levels and pericyte migration were even greater in the presence of
both DA and NE. This experimental condition mimics the in vivo
scenario of chronically stressed mice treated with DA and suggests
that NE reinforces the DA remodeling effect on tumor vasculature
during chronic stress. The mechanism of this NE effect was not
addressed in this study, but a potential explanation is that NE, by
acting through the β-adrenergic pathway, could increase cAMP levels,
which would stimulate pericyte migration. However, the question of
why NE alone does not promote pericyte recruitment remains un-
answered. It is conceivable that DA also activates additional signaling
pathways that are not triggered by NE and contribute to the unique
effects of DA on pericyte biology and vascular development. Alter-
natively, the rapid cAMP flux associated with NE (but not with DA
or NE plus DA treatment; Figure 4B, 10 minutes) may contribute to
differential effects.
The use of two PKA inhibitors and a PKA activator confirmed the
involvement of PKA in the DA-mediated effect on pericytes. Focal
adhesion kinase (FAK) is an important regulator of signaling pro-
cesses between the extracellular matrix and tumor cells [33,34].
PKA-mediated FAK phosphorylation can stimulate the binding of
FAK to Src kinase and the formation of the FAK-Src complex. At
focal adhesion sites, FAK activation enhances cytoskeletal reorganiza-
tion, cellular adhesion, and cell survival [35,36]. In addition, FAK
also promotes tumor cell migration and invasion [37]. These findings
suggest that FAK activation promotes pericyte recruitment and
might be involved in the DA stimulatory effect on pericytes. During
Figure 5. DA stimulates pericyte recruitment through DR1-cAMP-PKA signaling pathway. (A) DA induces association of DR1 to Gαs
protein. 10T1/2 pericyte cells were exposed to DA (10 μM) for 10 and 20 minutes. Pericyte lysates were then immunoprecipitated with
DR1 antibody and analyzed by Western blot analysis. Gαs was immunodetected using a specific anti-Gαs antibody (Abcam). DA caused
a 1.5-fold higher interaction between DR1 and Gαs after 10 minutes of exposure compared with untreated cells. The densitometric data
were normalized to a loading control (β-actin from original lysate) and are representative of two independent experiments. (B) Immuno-
fluorescence images (200×) from untreated and 10T1/2 cells exposed to DA (10 μM) for 10 minutes and stained for DR1 and Gαs
protein. Pericytes exposed to DA for 10 minutes showed an elongated, fibroblastic morphology compared to untreated cells. (C) Confocal
images (200×) from 10T/12 cells revealing colocalization of DR1 (red fluorescence) with RGS5 (green fluorescence) and colocalization of
mDR1 (red fluorescence) with desmin-positive cells (green fluorescence) in SKOV3ip1 tumor tissues. Yellow areas confirm the expression
of mDR1 in 10T/12 cells and in tumor pericytes. (D) DA and PKA activator dbcAMP caused a two-fold increase in pericyte migration. PKA
inhibitors KT5720 and H89 at 10 μM abrogated (25–30%) the stimulatory effect of DA on pericyte migration (†P < .05).
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DA treatment, FAK activation could occur through either increased
cAMP levels or activated PKA, leading to increased pericyte coverage
of tumor vessels. In summary, we have shown that DA effectively
blocks the deleterious effects of chronic stress on tumor vasculature.
The antiangiogenic and pro-vessel maturation effects of DA make
this catecholamine an attractive choice to improve the efficacy of
therapies for cancer and other diseases with abnormal vasculature.
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Figure W1. Expression of DA and β-adrenergic receptors in murine
pericyte 10T1/2 cells and MOEC. (A) RT-PCR analysis of mDR1 to
mDR5. (B) Protein expression of DR1, DR2 in pericytes, and MOEC.
(C) RNA expression of β-adrenergic receptors in pericytes andMOEC.
Figure W2. Pericyte coverage of SKOV3ip1 tumor endothelial
cells. Tumor tissues from mice treated with DA and SKF 82958
showed significantly higher percentage of pericyte coverage com-
pared to the control group (*P < .0001). Tumor tissues from mice
treated with parlodel showed an increase in pericyte coverage;
however, this increase was not statistical significant compared
to controls.
Figure W3. Hypoxic areas in ovarian cancer tumors from stressed mice. Representative confocal images (100×) of SKOV3ip1 tumor
tissues from chronically stressed mice stained for CA9 (green fluorescence). Tumors from stressed mice treated with DA (lower panel)
showed decreased regions of hypoxia (green fluorescence) compared with those from control (untreated) stressed mice (upper panel).
Figure W4. Ang1 expression in SKOV3ip1 tumor tissues from
stressed mice. Treatments of DA, DR1 agonist SKF 82958, and
DR2 agonist parlodel did not affect mRNA (A) and protein (B) expres-
sion of Ang1. Ang1 mRNA was determined by quantitative RT-PCR.
Ang1 protein was detected in tumor pericytes by a double immuno-
fluorescence staining for Ang1 (green fluorescence) and RGS5 (as
pericyte marker; red fluorescence).
Figure W5.Migration ofMOECs in the presence of DA, NE, and DA
antagonist. DA exposure resulted in a 22% (P < .05) decrease in
MOEC migration. This effect, however, was not significantly abol-
ished with either combined treatment of DA and DR1 antagonist
butaclamol (DA/butaclamol) or combined treatment of DA and
DR2 antagonist eticlopride (DA/eticlopride). MOEC migration was
not significantly affected by treatment with NE or DA + NE.
